Illumina has partnered with Vitrolife to sell our preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD) products in Europe, the Middle East, Africa, and the Americas. Vitrolife began taking customer orders in December of 2018 and transitioning all sales and support in early 2019. Both Illumina and Vitrolife are committed to ensuring a seamless transition.

VeriSeq PGS

A fully validated next-generation sequencing solution that provides accurate chromosome screening for selection of embryos most likely to be euploid.Read More...
Select Product(s)

VeriSeq PGS Kit (96 samples)



MiSeq Reagent Kit v3 - PGS (24 samples)



Product Highlights

The VeriSeq PGS Kit takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for selection of embryos most likely to be euploid. Preimplantation genetic screening (PGS) results generated using VeriSeq PGS are comparable to those achieved with the widely used array-based 24sure technology. In addition, NGS offers the opportunity for improved assay workflow, higher throughput, and enhanced performance.1

  • Industry-leading data quality: More than 90% of the world’s sequencing data is generated by Illumina sequencing by synthesis (SBS) chemistry*
  • Fast, streamlined workflow: Sample to answer in approximately 12 hours
  • High-throughput analysis: Screen up to 24 samples per run
Ultra-Low Input

NGS offers a highly sensitive method for screening embryos, requiring as little as 1 ng of DNA from a SurePlex DNA amplification reaction. DNA can be obtained from a blastomere biopsy, from a day 3 embryo, or from a trophectodermal (TE) biopsy from a blastocyst.

*Data calculations on file. Illumina, Inc., 2015.

Frequently Purchased Together


Method-Specific Workflow Example


Supporting Data and Figures


The 24sure Microarray has been discontinued. VeriSeq PGS provides an alternative solution for this application. Illumina remains committed to providing you with high-quality support and service.

Related Products

  1. Fiorentino F, Bono S, Biricik A, et al. Application of next-generation sequencing technology for comprehensive aneuploidy screening of blastocysts in clinical preimplantation genetic screening cycles. Hum Reprod. 2014;29(12):2802–2813.
  2. Yang Z, Liu J, Collins GS, Salem SA, et al. Selection of single blastocysts for fresh transfer via standard morphology assessment alone and with array CGH for good prognosis patients: results from a randomised pilot study. Mol Cytogenet. 2012;5: 24.